<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: raise additional capital", fill: "#e08d3c"},
{source: "4: raise additional capital", target: "4: operations", fill: "#e08d3c"},
{source: "4: operations", target: "4: potential products", fill: "#e08d3c"},
{source: "4: raise additional capital", target: "5: internally generated cash flow will", fill: "#007fff"},
{source: "5: internally generated cash flow will", target: "5: fund development", fill: "#007fff"},
{source: "5: fund development", target: "5: commercialization", fill: "#007fff"},
{source: "5: commercialization", target: "5: product candidates", fill: "#007fff"},
{source: "5: product candidates", target: "5: additional financial resources", fill: "#007fff"},
{source: "5: internally generated cash flow will", target: "6: future capital requirements will depend", fill: "#de3163"},
{source: "6: future capital requirements will depend", target: "6: development programs", fill: "#de3163"},
{source: "6: development programs", target: "6: timing costs", fill: "#de3163"},
{source: "6: timing costs", target: "6: conducting clinical", fill: "#de3163"},
{source: "6: conducting clinical", target: "6: regulatory approvals", fill: "#de3163"},
{source: "6: regulatory approvals", target: "6: pursuing patent prosecutions", fill: "#de3163"},
{source: "6: pursuing patent prosecutions", target: "6: competing technological", fill: "#de3163"},
{source: "6: competing technological", target: "6: market developments", fill: "#de3163"},
{source: "6: market developments", target: "6: renegotiate", fill: "#de3163"},
{source: "6: renegotiate", target: "6: lease obligations", fill: "#de3163"},
{source: "6: lease obligations", target: "6: commercialization", fill: "#de3163"},
{source: "6: commercialization", target: "6: activities", fill: "#de3163"},
{source: "6: activities", target: "6: facility", fill: "#de3163"},
{source: "6: facility", target: "6: expansions", fill: "#de3163"},
{source: "6: expansions", target: "6: litigation", fill: "#de3163"},
{source: "6: litigation", target: "6: administrative proceedings", fill: "#de3163"},
{source: "6: administrative proceedings", target: "6: intellectual property", fill: "#de3163"},
{source: "6: intellectual property", target: "6: third party intellectual", fill: "#de3163"},
{source: "6: third party intellectual", target: "6: property through licensing agreements", fill: "#de3163"},
{source: "6: future capital requirements will depend", target: "8: based on", fill: "#cc4e5c"},
{source: "8: based on", target: "8: development activities", fill: "#cc4e5c"},
{source: "8: development activities", target: "8: funding from", fill: "#cc4e5c"},
{source: "8: funding from", target: "8: collaborators", fill: "#cc4e5c"},
{source: "8: based on", target: "21: successfully access additional capital", fill: "#c2b280"},
{source: "21: successfully access additional capital", target: "21: scale back delay", fill: "#c2b280"},
{source: "21: scale back delay", target: "21: terminate one", fill: "#c2b280"},
{source: "21: terminate one", target: "21: development", fill: "#c2b280"},
{source: "21: development", target: "21: programs curtail capital expenditures", fill: "#c2b280"},
{source: "21: programs curtail capital expenditures", target: "21: activities", fill: "#c2b280"},
{source: "21: successfully access additional capital", target: "22: relinquish", fill: "#db7093"},
{source: "22: relinquish", target: "22: technology", fill: "#db7093"},
{source: "22: technology", target: "22: candidates", fill: "#db7093"},
{source: "22: candidates", target: "22: licenses on unfavorable terms either", fill: "#db7093"},
{source: "22: licenses on unfavorable terms either", target: "22: which would reduce", fill: "#db7093"},
{source: "22: which would reduce", target: "22: ultimate value", fill: "#db7093"},
{source: "22: relinquish", target: "33: Commercializing ", fill: "#ff003f"},
{source: "33: Commercializing ", target: "33: potential products", fill: "#ff003f"},
{source: "33: potential products", target: "33: depends on successful completion", fill: "#ff003f"},
{source: "33: depends on successful completion", target: "33: additional research", fill: "#ff003f"},
{source: "33: additional research", target: "33: development", fill: "#ff003f"},
{source: "33: development", target: "33: both preclinical development", fill: "#ff003f"},
{source: "33: both preclinical development", target: "33: clinical trials", fill: "#ff003f"},
{source: "33: Commercializing ", target: "START_HERE", fill: "#ff003f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Potential_output">Potential output</a></td>
      <td>In economics, potential output (also referred to as "natural gross domestic product") refers to the highest level of real gross domestic product (potential output) that can be sustained over the long term. Actual output happens in real life while potential output shows the level that could be achieved.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Potential_energy">Potential energy</a></td>
      <td>In physics, potential energy is the energy held by an object because of its position relative to other objects, stresses within itself, its electric charge, or other factors.Common types of potential energy include the gravitational potential energy of an object that depends on its mass and its distance from the center of mass of another object, the elastic potential energy of an extended spring, and the electric potential energy of an electric charge in an electric field. The unit for energy in the International System of Units (SI) is the joule, which has the symbol J.\nThe term potential energy was introduced by the 19th-century Scottish engineer and physicist William Rankine, although it has links to Greek philosopher Aristotle's concept of potentiality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Action_potential">Action potential</a></td>
      <td>In physiology, an action potential (AP) occurs when the membrane potential of a specific cell location rapidly rises and falls. This depolarization then causes adjacent locations to similarly depolarize.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chemical_potential">Chemical potential</a></td>
      <td>In thermodynamics, the chemical potential of a species is the energy that can be absorbed or released due to a change of the particle number of the given species, e.g. in a chemical reaction or phase transition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reduction_potential">Reduction potential</a></td>
      <td>Redox potential (also known as oxidation / reduction potential, ORP, pe, \n  \n    \n      \n        \n          E\n          \n            r\n            e\n            d\n          \n        \n      \n    \n    {\displaystyle E_{red}}\n  , or \n  \n    \n      \n        \n          E\n          \n            h\n          \n        \n      \n    \n    {\displaystyle E_{h}}\n  ) is a measure of the tendency of a chemical species to acquire electrons from or lose electrons to an electrode and thereby be reduced or oxidised respectively. Redox potential is measured in volts (V), or millivolts (mV).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Delta_potential">Delta potential</a></td>
      <td>In quantum mechanics the delta potential is a potential well mathematically described by the Dirac delta function - a generalized function. Qualitatively, it corresponds to a potential which is zero everywhere, except at a single point, where it takes an infinite value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minimum_viable_product">Minimum viable product</a></td>
      <td>A minimum viable product (MVP) is a version of a product with just enough features to be usable by early customers who can then provide feedback for future product development.A focus on releasing an MVP means that developers potentially avoid lengthy and (ultimately) unnecessary work. Instead, they iterate on working versions and respond to feedback, challenging and validating assumptions about a product's requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Potential_flow">Potential flow</a></td>
      <td>In fluid dynamics, potential flow describes the velocity field as the gradient of a scalar function: the velocity potential. As a result, a potential flow is characterized by an irrotational velocity field, which is a valid approximation for several applications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>TARGETED GENETICS CORP /WA/      Item 1A Risk Factors             In addition to the other information contained in this annual report,     you <font color="blue">should carefully</font> read and consider the <font color="blue">following risk factors</font></td>
    </tr>
    <tr>
      <td>If any of     these <font color="blue">risks actually</font> occur, our business, operating results or financial     <font color="blue">condition could</font> be harmed</td>
    </tr>
    <tr>
      <td>This could cause the <font color="blue">trading price</font> of our stock     to decline, and you <font color="blue">could lose</font> all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       If we are unable to <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> capital</font> when needed, we will be unable     to conduct our <font color="blue">operations</font> and develop our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">internally generated cash flow will</font> not <font color="blue">fund <font color="blue">development</font></font> and     <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font>, we will require substantial     <font color="blue"><font color="blue">additional</font> <font color="blue">financial resources</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital <font color="blue"><font color="blue">requirement</font>s</font> will depend</font>     on many factors, including:         •  the rate and extent of scientific progress in our research and     <font color="blue"><font color="blue">development</font> programs</font>;         •  the timing, costs and scope of, and our success in, <font color="blue">conducting clinical</font>     trials, obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> and <font color="blue">pursuing patent prosecutions</font>;         •  <font color="blue">competing technological</font> and <font color="blue">market <font color="blue">development</font>s</font>;         •  the ability to re-negotiate any <font color="blue">lease <font color="blue">obligation</font>s</font>;          •   the  timing  and  costs  of,  and  our  success  in any product     <font color="blue">commercialization</font>  <font color="blue">activities</font>  and  <font color="blue">facility</font>  <font color="blue">expansions</font>,  if  and  as     required; and         •  the expense and outcome of any <font color="blue">litigation</font> or <font color="blue"><font color="blue">administrative</font> proceedings</font>     involving our <font color="blue"><font color="blue">intellectual</font> property</font>, or access to <font color="blue"><font color="blue">third party</font> <font color="blue">intellectual</font></font>     <font color="blue">property through licensing <font color="blue"><font color="blue">agreement</font>s</font></font></td>
    </tr>
    <tr>
      <td>We expect that our cash and <font color="blue">cash equivalents at</font> <font color="blue">December </font>31, 2005,     plus the <font color="blue">funding from</font> our partners and the <font color="blue">proceeds from</font> the sale of common     stock in March 2006 will be sufficient to fund our <font color="blue">operations</font> into the first     quarter of 2007</td>
    </tr>
    <tr>
      <td>This estimate is <font color="blue">based on</font> our ability to perform planned     research and <font color="blue">development</font> <font color="blue">activities</font> and the receipt of planned <font color="blue">funding from</font>     our  <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, we owe approximately dlra8dtta2 million in     <font color="blue">aggregate principal amount under two</font> notes payable to Biogen Idec</td>
    </tr>
    <tr>
      <td>The     notes’ terms require us to make <font color="blue">scheduled principal payments</font> of dlra3dtta2 million     in August 2007 and dlra2dtta5 million in each of August 2008 and 2009</td>
    </tr>
    <tr>
      <td>We will     need to <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> capital</font> to make the <font color="blue">scheduled payments</font> and to repay     these notes</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>sources of <font color="blue">financing could involve one</font> or more of     the following:         •  <font color="blue">entering into <font color="blue">additional</font> product <font color="blue">development</font></font> and <font color="blue">funding <font color="blue"><font color="blue">collaboration</font>s</font></font>     or other <font color="blue">strategic <font color="blue">transaction</font>s</font>, or extending or expanding our current     <font color="blue"><font color="blue">collaboration</font>s</font>;         •  <font color="blue">issuing equity</font> in the public or <font color="blue">private markets</font>; or         •  <font color="blue">issuing debt</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [62]Table of <font color="blue">Contents       </font>      <font color="blue">Additional </font><font color="blue">funding may</font> not be available to <font color="blue">us on reasonable terms</font>, if     at all</td>
    </tr>
    <tr>
      <td>Our ability to issue equity, and our ability to issue it at the     current <font color="blue">market price</font>, may be <font color="blue">adversely affected by</font> the fact that we are     presently  ineligible  under SEC rules to utilize Form S-3 for primary     offerings  of  our  securities  because the aggregate market value our     outstanding <font color="blue">common stock</font> held by non-affiliates is less than dlra75 million</td>
    </tr>
    <tr>
      <td>The perceived <font color="blue">risk associated with</font> the <font color="blue">possible sale</font> of a large number     of <font color="blue">shares could</font> cause some of our stockholders to sell their stock, thus     causing  the  price  of  our  stock to decline</td>
    </tr>
    <tr>
      <td>In addition, actual or     anticipated  downward  pressure  on  our  stock price due to actual or     anticipated sales of <font color="blue">stock could</font> cause some <font color="blue">institution</font>s or <font color="blue">individuals</font> to     engage in short sales of our <font color="blue">common stock</font>, which may itself cause the price     of our stock to decline</td>
    </tr>
    <tr>
      <td>If our <font color="blue">stock price declines</font>, we may be unable to <font color="blue">raise <font color="blue">additional</font></font>     capital</td>
    </tr>
    <tr>
      <td>A <font color="blue">sustained <font color="blue">inability</font></font> to <font color="blue"><font color="blue">raise capital</font> could force us</font> to go out of     business</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>declines in the price of our common <font color="blue">stock could</font> also     impair our ability to attract and retain <font color="blue">qualified employees</font>, reduce the     liquidity of our <font color="blue">common stock</font> and result in the delisting of our common     stock from the <font color="blue">NASDAQ Capital Market</font></td>
    </tr>
    <tr>
      <td>The funding that we expect to receive from our <font color="blue"><font color="blue">collaboration</font>s</font> depends     on  continued  scientific  progress  under  the  <font color="blue">collaboration</font> and our     <font color="blue"><font color="blue">collaborator</font>s</font>’  ability  and  <font color="blue">willingness</font>  to  continue  or extend the     <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">successfully</font> access <font color="blue">additional</font> capital</font>,     we may need to scale back, delay or <font color="blue">terminate one</font> or more of our <font color="blue">development</font>     programs, curtail capital <font color="blue">expenditures</font> or reduce other operating <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We may also be required to <font color="blue">relinquish</font> some rights to our <font color="blue">technology</font> or     <font color="blue">product <font color="blue">candidates</font></font> or grant or take licenses on unfavorable terms, either of     <font color="blue">which would reduce</font> the <font color="blue">ultimate value</font> to us of our <font color="blue">technology</font> or product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We expect to continue to operate at a loss and <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our revenue has <font color="blue">been derived under <font color="blue">collaborative</font></font>     research and <font color="blue">development</font> <font color="blue"><font color="blue">agreement</font>s</font> relating to the <font color="blue">development</font> of our     potential <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have incurred, and <font color="blue">will continue</font> to incur     for the foreseeable future, <font color="blue">significant</font> expense to develop our research and     <font color="blue"><font color="blue">development</font> programs</font>, conduct preclinical studies and <font color="blue"><font color="blue">clinical trial</font>s</font>, seek     <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">provide general</font> and     <font color="blue"><font color="blue">administrative</font> support</font> for these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>As a result, we have incurred     <font color="blue">significant</font> net losses since inception, and we expect to continue to incur     substantial <font color="blue">additional</font> losses in the future</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had     an <font color="blue">accumulated deficit</font> of dlra250dtta0 million</td>
    </tr>
    <tr>
      <td>We may never generate profits and,     if  we  do  <font color="blue">become profitable</font>, we may be unable to sustain or increase     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>All of our <font color="blue">product <font color="blue">candidates</font></font> are in early-stage <font color="blue"><font color="blue">clinical trial</font>s</font> or     preclinical <font color="blue">development</font>, and if we are unable to <font color="blue">successfully</font> develop and     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> we will be unable to generate     sufficient capital to maintain our business</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2005, IAVI initiated a <font color="blue">Phase II </font>trial for our HIV/ AIDS     <font color="blue">vaccine <font color="blue">product candidate</font></font> in South Africa</td>
    </tr>
    <tr>
      <td>In October 2005, we initiated a     second Phase I trial for our <font color="blue"><font color="blue">inflammatory</font> arthritis <font color="blue">product candidate</font></font> in the     <font color="blue">United States and Canada</font></td>
    </tr>
    <tr>
      <td>We will not generate any <font color="blue">product revenue</font> for at     least  several  years and then only if we can <font color="blue">successfully</font> develop and     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercializing </font>our <font color="blue"><font color="blue">potential product</font>s</font>     <font color="blue"><font color="blue">depends on</font> successful <font color="blue">completion</font></font> of <font color="blue">additional</font> research and <font color="blue">development</font> and     testing, in both preclinical <font color="blue">development</font> and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Clinical     </font><font color="blue">trials may</font> take <font color="blue">several years</font> or more to complete</td>
    </tr>
    <tr>
      <td>The commencement, cost     and rate of <font color="blue">completion</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font> may vary or be delayed for     many reasons, including the <font color="blue">risks discussed elsewhere</font> in this section</td>
    </tr>
    <tr>
      <td>If we     are unable to <font color="blue">successfully</font> complete preclinical and clinical <font color="blue">development</font> of     some or all of our <font color="blue">product <font color="blue">candidates</font></font> in a <font color="blue">timely manner</font>, we may be unable     to generate sufficient <font color="blue">product revenue</font> to maintain our business</td>
    </tr>
    <tr>
      <td>Even if our <font color="blue"><font color="blue">potential product</font>s</font> succeed in <font color="blue"><font color="blue">clinical trial</font>s</font> and are     approved for marketing, these <font color="blue">products may never</font> achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in <font color="blue">commercializing</font> our <font color="blue">product <font color="blue">candidates</font></font> for any     reason, including <font color="blue">greater <font color="blue"><font color="blue">effective</font>ness</font></font> or <font color="blue">economic feasibility</font> of competing     products or <font color="blue">treatments</font>, the failure of the <font color="blue">medical community</font> or the public     to accept or use any products <font color="blue">based on</font> gene delivery, inadequate marketing     and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font> or other <font color="blue">reasons discussed elsewhere</font> in this     section,  we  will be unable to generate sufficient <font color="blue">product revenue</font> to     maintain our business</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [63]Table of <font color="blue">Contents       </font>Failure to <font color="blue">recruit subjects</font> <font color="blue">could delay</font> or prevent <font color="blue"><font color="blue">clinical trial</font>s</font> of our     <font color="blue"><font color="blue">potential product</font>s</font>, which <font color="blue">could delay</font> or prevent the <font color="blue">development</font> of     <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Identifying </font>and qualifying subjects to <font color="blue">participate</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>     of our <font color="blue"><font color="blue">potential product</font>s</font> is <font color="blue">critically</font> important to our success</td>
    </tr>
    <tr>
      <td>The timing     of our <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">depends on</font> the <font color="blue">speed at which</font> we can <font color="blue">recruit subjects</font>     to <font color="blue">participate</font> in testing our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have experienced delays     in some of our <font color="blue"><font color="blue">clinical trial</font>s</font>, and we may experience similar delays in the     future</td>
    </tr>
    <tr>
      <td>If subjects are unwilling to <font color="blue">participate</font> in our <font color="blue"><font color="blue">gene therapy</font> trials</font>     because of <font color="blue">negative publicity from <font color="blue">adverse events</font></font> in the bio<font color="blue">technology</font> or     <font color="blue"><font color="blue">gene therapy</font> industries</font> or for other reasons, including <font color="blue"><font color="blue">competitive</font> clinical</font>     trials  for  similar  <font color="blue">patient populations</font>, the timeline for recruiting     subjects, conducting trials and obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> of potential     <font color="blue">products will</font> be delayed</td>
    </tr>
    <tr>
      <td>These delays could result in <font color="blue">increased costs</font>,     delays  in  advancing  our  product <font color="blue">development</font>, delays in testing the     <font color="blue"><font color="blue">effective</font>ness</font>  of our <font color="blue">technology</font> or <font color="blue">termination</font> of the <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue">altogether</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">regulatory</font> approval</font> process for our <font color="blue">product <font color="blue">candidates</font></font> is costly,     time-consuming and subject to unpredictable changes and delays, and our     <font color="blue">product <font color="blue">candidates</font></font> may never receive <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>No  <font color="blue"><font color="blue">gene therapy</font> products</font> have received <font color="blue"><font color="blue">regulatory</font> approval</font> for     <font color="blue">marketing from</font> the US Food and Drug Administration, or FDA Because our     <font color="blue">product <font color="blue">candidates</font></font> involve new and <font color="blue">unproven <font color="blue">technologies</font></font>, we believe that     the <font color="blue"><font color="blue">regulatory</font> approval</font> process may proceed more <font color="blue">slowly compared</font> to clinical     <font color="blue">trials involving traditional drugs</font></td>
    </tr>
    <tr>
      <td>The FDA and applicable state and foreign     <font color="blue">regulators</font> must conclude at each stage of <font color="blue">clinical testing</font> that our clinical     data suggest acceptable levels of safety in order for us to proceed to the     next stage of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">gene therapy</font> <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue">conducted at <font color="blue">institution</font>s</font> that receive funding for <font color="blue">recombinant</font> DNA research     from the NIH, are subject to review by the NIH’s Office of Bio<font color="blue">technology</font>     Activities RAC Although NIH <font color="blue">guidelines</font> do not have <font color="blue"><font color="blue">regulatory</font> status</font>, the     RAC <font color="blue">review process</font> can impede the <font color="blue">initiation</font> of the trial, even if the FDA     has reviewed the trial and approved its <font color="blue">initiation</font></td>
    </tr>
    <tr>
      <td>Moreover, before a     <font color="blue">clinical trial</font> can <font color="blue">begin at</font> an NIH-funded <font color="blue">institution</font>, that <font color="blue">institution</font>’s     <font color="blue">Institutional Biosafety Committee </font>must review the proposed <font color="blue">clinical trial</font> to     assess the safety of the trial</td>
    </tr>
    <tr>
      <td>The  <font color="blue">regulatory</font>  process  for our <font color="blue">product <font color="blue">candidates</font></font> is costly,     time-consuming and subject to <font color="blue">unpredictable delays</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial</font>     <font color="blue"><font color="blue">requirement</font>s</font> of the FDA, NIH and other agencies and the criteria these     <font color="blue">regulators</font> use to determine the safety and efficacy of a <font color="blue">product candidate</font>     <font color="blue">vary <font color="blue">substantially</font> according</font> to the type, complexity, novelty and intended     use  of  the  <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>     governing <font color="blue"><font color="blue">gene therapy</font> products</font> have changed <font color="blue">frequently</font> and may change in     the future</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot predict how long</font> it will take or how much     it will cost to obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for <font color="blue"><font color="blue">clinical trial</font>s</font> or for     <font color="blue">manufacturing</font>  or marketing our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Some or all of our     product  <font color="blue">candidates</font>  may  never receive <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>A product     candidate  that  appears  promising  at  an <font color="blue">early stage</font> of research or     <font color="blue">development</font>  may  not result in a <font color="blue">commercially successful product</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">clinical trial</font>s</font> may fail to <font color="blue">demonstrate</font> the safety and efficacy of a product     candidate or a <font color="blue">product candidate</font> may generate unacceptable side affects or     other <font color="blue">problems during</font> or after <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Should this occur, we may     have to delay or discontinue <font color="blue">development</font> of the <font color="blue">product candidate</font>, and the     partner, if any, that supports <font color="blue">development</font> of that <font color="blue">product candidate</font> may     terminate its support</td>
    </tr>
    <tr>
      <td>Delay or failure to obtain, or unexpected costs in     obtaining, the <font color="blue"><font color="blue">regulatory</font> approval</font> <font color="blue">necessary</font> to bring a <font color="blue">potential product</font> to     market could decrease our ability to generate sufficient <font color="blue">product revenue</font> to     maintain our business</td>
    </tr>
    <tr>
      <td>If we are unable to obtain or maintain licenses for <font color="blue">necessary</font> third-party     <font color="blue">technology</font> on acceptable terms or to develop alternative <font color="blue">technology</font>, we may     be unable to develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into exclusive</font> and <font color="blue"><font color="blue">nonexclusive license</font> <font color="blue"><font color="blue">agreement</font>s</font></font>     that give us and our <font color="blue">partners rights</font> to <font color="blue">use <font color="blue">technologies</font></font> owned or licensed     by commercial and <font color="blue">academic <font color="blue">organizations</font></font> in the research, <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>For example, we have a gene     therapy <font color="blue">technology</font> license <font color="blue">agreement</font> with Amgen Inc, or Amgen, as the     successor to Immunex Corporation, or Immunex, under which we have license     rights to certain Immunex <font color="blue">proprietary</font> <font color="blue">technology</font> specifically applicable to     gene  therapy  <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td><font color="blue">In a February </font>2004 letter, Amgen took the     position that we are not licensed, either exclusively or <font color="blue">nonexclusively</font>, to     use Immunex <font color="blue"><font color="blue">intellectual</font> property</font> covering TNFR:Fc or <font color="blue">therapeutic</font> uses for                                         18       _________________________________________________________________    [64]Table of <font color="blue">Contents       </font>TNFR:Fc</td>
    </tr>
    <tr>
      <td>We have responded with a <font color="blue">letter confirming</font> our confidence that the     <font color="blue">gene therapy</font> <font color="blue">technology</font> license <font color="blue">agreement</font> provides us with an exclusive     <font color="blue">worldwide license</font> to use the <font color="blue">gene construct coding</font> for TNFR:Fc for gene     therapy  <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We  have  had  and  continue  to  have further     <font color="blue">communications with</font> Amgen regarding our <font color="blue">differences</font></td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>our     confidence, it is possible that a resolution of those <font color="blue">differences</font>, through     <font color="blue">litigation</font>  or  otherwise, could cause delay or <font color="blue">discontinuation</font> of our     <font color="blue">development</font> of tgAAC94 or our <font color="blue">inability</font> to <font color="blue">commercialize</font> any resulting     product</td>
    </tr>
    <tr>
      <td>We believe that we will need to obtain <font color="blue">additional</font> licenses to use     patents and unpatented <font color="blue">technology</font> owned or <font color="blue">licensed by others</font> for use,     compositions, methods, processes to <font color="blue">manufacture</font> compositions, processes to     <font color="blue">manufacture</font>  and  purify  gene  delivery  <font color="blue">product <font color="blue">candidates</font></font> and other     <font color="blue">technologies</font> and processes for our present and potential <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to maintain our <font color="blue">current licenses</font> for third-party <font color="blue">technology</font>     or obtain <font color="blue">additional</font> licenses on acceptable terms, we may be required to     expend <font color="blue">significant</font> time and resources to develop or <font color="blue">license replacement</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we are unable to do so, we may be unable to develop or     <font color="blue">commercialize</font> the affected <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, the license     <font color="blue"><font color="blue">agreement</font>s</font> for <font color="blue">technology</font> for which we hold <font color="blue">exclusive licenses typically</font>     <font color="blue">contain provisions</font> that require us to meet minimum <font color="blue">development</font> milestones in     order to maintain the <font color="blue">license on</font> an <font color="blue">exclusive basis</font> for some or all fields     of  the  license</td>
    </tr>
    <tr>
      <td>We  also  have  license  <font color="blue"><font color="blue">agreement</font>s</font> for some of our     <font color="blue">technologies</font>, which may require us to <font color="blue">sublicense certain</font> of our rights</td>
    </tr>
    <tr>
      <td>If     we do not meet these <font color="blue"><font color="blue">requirement</font>s</font>, our <font color="blue">licensor may convert</font> all or a portion     of the license to a <font color="blue">nonexclusive license</font> or, in some cases, terminate the     license</td>
    </tr>
    <tr>
      <td>In many cases, patent prosecution of our licensed <font color="blue">technology</font> is     <font color="blue">controlled solely by</font> the licensor</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">licensors</font> fail</font> to obtain and     maintain  patent  or other protection for the <font color="blue"><font color="blue">proprietary</font> <font color="blue">intellectual</font></font>     property we <font color="blue">license from them</font>, we <font color="blue">could lose</font> our rights to the <font color="blue">intellectual</font>     property  or  our  <font color="blue">exclusivity</font>  with  respect to those rights, and our     <font color="blue"><font color="blue">competitors</font> could market competing products using</font> the <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td><font color="blue">Licensing </font>of <font color="blue"><font color="blue">intellectual</font> property</font> is of critical importance to our business     and  involves  complex  legal,  business  and <font color="blue">scientific issues</font> and is     complicated by the rapid pace of scientific <font color="blue">discovery</font> in our industry</td>
    </tr>
    <tr>
      <td>Disputes may arise regarding <font color="blue"><font color="blue">intellectual</font> property</font> subject to a licensing     <font color="blue">agreement</font>, including:         •  the scope of <font color="blue">rights granted under</font> the license <font color="blue">agreement</font> and other     interpretation-related issues;          •   the  extent  to  which our <font color="blue">technology</font> and <font color="blue">processes infringe on</font>     <font color="blue"><font color="blue">intellectual</font> property</font> of the licensor that is not subject to the licensing     <font color="blue">agreement</font>;         •  the <font color="blue">sublicensing</font> of patent and other <font color="blue">rights under</font> our <font color="blue">collaborative</font>     <font color="blue">development</font> <font color="blue">relationship</font>s;         •  the ownership of inventions and know-how resulting from the joint     creation or use of <font color="blue"><font color="blue">intellectual</font> property</font> by our <font color="blue">licensors</font> and us and our     partners; and         •  the priority of invention of patented <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If disputes over <font color="blue"><font color="blue">intellectual</font> property</font> that we have <font color="blue">licensed prevent</font>     or impair our ability to maintain our <font color="blue">current licensing arrangements on</font>     acceptable terms, we may be unable to <font color="blue">successfully</font> develop and <font color="blue">commercialize</font>     the affected <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>involving <font color="blue"><font color="blue">intellectual</font> property</font>, product <font color="blue">liability</font> or other     claims and <font color="blue"><font color="blue">product recall</font>s could</font> strain our resources, subject us to     <font color="blue">significant</font> <font color="blue">liability</font>, damage our reputation or result in the <font color="blue">in<font color="blue">validation</font></font>     of our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>As our product <font color="blue">development</font> efforts progress, <font color="blue">most particularly</font> in     <font color="blue">potentially</font> <font color="blue">significant</font> markets such as HIV/ AIDS, <font color="blue">congestive heart failure</font>     or <font color="blue"><font color="blue">inflammatory</font> arthritis therapies</font>, the <font color="blue">risk increases</font> that <font color="blue">others may</font>     claim  that  our  processes  and  <font color="blue">product <font color="blue">candidates</font></font> infringe on their     <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">administrative</font> proceedings</font>,     <font color="blue">litigation</font> or both may be <font color="blue">necessary</font> to enforce our <font color="blue"><font color="blue">intellectual</font> property</font>     rights  or determine the rights of others</td>
    </tr>
    <tr>
      <td><font color="blue">Defending </font>or pursuing these     claims, <font color="blue">regardless</font> of their merit, would be costly and would likely divert     management’s attention and resources away from our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If there were     to be an <font color="blue">adverse outcome</font> in <font color="blue">litigation</font> or an <font color="blue">interference proceeding</font>, we     <font color="blue">could face potential <font color="blue">liability</font></font> for <font color="blue">significant</font> damages or be required to     obtain a license to the <font color="blue">patented process</font> or <font color="blue">technology</font> at issue, or both</td>
    </tr>
    <tr>
      <td>If     we are unable to obtain a <font color="blue">license on</font> acceptable terms, or to develop or     obtain alternative <font color="blue">technology</font> or processes, we                                         19       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>may be unable to <font color="blue">manufacture</font> or market any product or <font color="blue">potential product</font> that     uses the <font color="blue">affected process</font> or <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Clinical trials and the marketing of any <font color="blue"><font color="blue">potential product</font>s</font> may expose     us to <font color="blue">liability</font> claims resulting from the testing or use of our products</td>
    </tr>
    <tr>
      <td>Gene  therapy <font color="blue">treatments</font> are new and unproven, and <font color="blue">potential known</font> and     unknown  side  effects  of <font color="blue"><font color="blue">gene therapy</font> may</font> be serious and <font color="blue">potentially</font>     life-threatening</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims may be made by <font color="blue">clinical trial</font>     participants, consumers, healthcare providers or other sellers or users of     our products</td>
    </tr>
    <tr>
      <td>Although we currently maintain <font color="blue">liability</font> insurance, the costs     of product <font color="blue">liability</font> and other claims <font color="blue">against us may exceed</font> our insurance     coverage</td>
    </tr>
    <tr>
      <td>In addition, we may require increased <font color="blue">liability</font> coverage as     <font color="blue">additional</font> <font color="blue">product <font color="blue">candidates</font></font> are used in <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td><font color="blue">Liability </font>insurance is expensive and may not continue to be <font color="blue">available on</font>     acceptable terms</td>
    </tr>
    <tr>
      <td>A product <font color="blue">liability</font> or other claim or <font color="blue">product recall</font> not     <font color="blue">covered by</font> or exceeding our insurance coverage could <font color="blue">significant</font>ly harm our     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In addition, adverse publicity resulting from a product     recall or a <font color="blue">liability</font> claim against us, one of our partners or another gene     therapy company could <font color="blue">significant</font>ly harm our reputation and make it more     <font color="blue">difficult</font> to obtain the funding and <font color="blue">collaborative</font> <font color="blue">partnerships</font> <font color="blue">necessary</font> to     maintain our business</td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">collaborative</font> partners, we may be unable to develop our     <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>A  portion  of  our  operating  expenses are <font color="blue">funded through</font> our     <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> with third parties</td>
    </tr>
    <tr>
      <td>We currently have strategic     <font color="blue">partnerships</font>  with two bio<font color="blue">technology</font> companies, <font color="blue">Sirna Therapeutics </font>and     Celladon, <font color="blue">one public health organization</font>, IAVI, and through a contract with     a US <font color="blue"><font color="blue">government</font> agency</font>, NIAID, that provide for funding, <font color="blue">collaborative</font>     <font color="blue">development</font>, <font color="blue"><font color="blue">intellectual</font> property</font> rights or expertise to develop certain of     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>With limited exceptions, each <font color="blue">collaborator</font> has the     right to terminate its <font color="blue">obligation</font> to <font color="blue">provide research funding at</font> any time     for scientific or business reasons</td>
    </tr>
    <tr>
      <td>In addition, to the extent that funding     is <font color="blue">provided by</font> a <font color="blue">collaborator</font> for non-program-specific uses, the loss of     <font color="blue">significant</font> amounts of <font color="blue">collaborative</font> funding could result in the delay,     reduction or <font color="blue">termination</font> of <font color="blue">additional</font> research and <font color="blue"><font color="blue">development</font> programs</font>, a     reduction  in  capital  <font color="blue">expenditures</font> or business <font color="blue">development</font> and other     operating <font color="blue">activities</font>, or any <font color="blue">combination</font> of these measures</td>
    </tr>
    <tr>
      <td>For example, we     have a <font color="blue">collaborative</font> <font color="blue">development</font> <font color="blue">agreement</font> with IAVI, <font color="blue">which expires</font> in     <font color="blue">December </font> 2006, that we expect to <font color="blue">provide us with funding</font> to reimburse     research and <font color="blue">development</font> and <font color="blue">manufacturing</font> expenses we incur in <font color="blue">connection</font>     with the <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>As a result, a <font color="blue">significant</font> portion of our operating     expenses  are  funded  through our <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font> with IAVI     Additionally, IAVI <font color="blue">directly funds</font> the <font color="blue">Phase II </font><font color="blue">clinical trial</font> for our HIV/     AIDS <font color="blue">vaccine <font color="blue">product candidate</font></font></td>
    </tr>
    <tr>
      <td>If we do not attract and retain <font color="blue">qualified personnel</font>, we may be unable to     develop and <font color="blue">commercialize</font> some of our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends</font> in large part on our ability to attract and     retain  key  technical and <font color="blue">management personnel</font></td>
    </tr>
    <tr>
      <td>All of our employees,     including our executive officers, can terminate their <font color="blue">employment</font> with us at     any time</td>
    </tr>
    <tr>
      <td>We have programs in place designed to retain personnel, including     <font color="blue"><font color="blue">competitive</font> compensation packages</font> and programs to create a positive work     <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>Other companies, research and academic <font color="blue">institution</font>s and other     <font color="blue">organizations</font> in our <font color="blue">field compete intensely</font> for employees, however, and we     may  be  unable to retain our <font color="blue">existing personnel</font> or attract <font color="blue">additional</font>     <font color="blue">qualified employees</font> and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">significant</font> turnover     or <font color="blue">difficult</font>y in <font color="blue">recruiting new personnel</font>, our research and <font color="blue">development</font> of     <font color="blue">product <font color="blue">candidates</font></font> could be delayed and we could experience <font color="blue">difficult</font>y in     <font color="blue">generating sufficient revenue</font> to maintain our business</td>
    </tr>
    <tr>
      <td>The reduction in <font color="blue">workforce associated with</font> our <font color="blue">recent <font color="blue">restructuring</font></font> of     <font color="blue">operations</font> may impair our ability to develop our <font color="blue">product <font color="blue">candidates</font></font> and harm     our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>January 24, 2006 we <font color="blue">restructured</font> our <font color="blue">operations</font> to <font color="blue">concentrate</font> our     <font color="blue">resources on generating data from</font> the <font color="blue"><font color="blue">clinical trial</font>s</font> of our <font color="blue">inflammatory</font>     arthritis <font color="blue">product candidate</font>, maintaining our <font color="blue">manufacturing</font> <font color="blue">capabilities</font> and     advancing  our  funded  product  <font color="blue">development</font>  efforts</td>
    </tr>
    <tr>
      <td>As part of this     <font color="blue">restructuring</font> we eliminated 26 positions, which reduced our <font color="blue">workforce by</font>     approximately 27prca, including scientific, <font color="blue">operations</font> and <font color="blue">administrative</font>     functions that were not required to support our programs</td>
    </tr>
    <tr>
      <td>This <font color="blue">restructuring</font>     primarily affected earlier-stage product <font color="blue">discovery</font> and <font color="blue">preclinical product</font>     <font color="blue">development</font> efforts, small-scale vector <font color="blue">manufacturing</font> employees,                                         20       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font><font color="blue">management positions</font> and <font color="blue">operations</font> and general and <font color="blue"><font color="blue">administrative</font> support</font></td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">terminated employees</font> possess <font color="blue">specific knowledge</font> or expertise     that <font color="blue">may later prove</font> to be important to our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As a result of these     factors,  our ability to develop our <font color="blue">product <font color="blue">candidates</font></font> and respond to     <font color="blue">challenges</font> in the <font color="blue">future may</font> be impaired and we may not be able to take     advantage of new business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>If our partners or scientific <font color="blue">consultants</font> terminate, reduce or delay our     <font color="blue"><font color="blue">relationship</font>s with them</font>, we may be unable to develop our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Our partners provide funding, manage <font color="blue">regulatory</font> filings, aid and     augment our <font color="blue">internal research</font> and <font color="blue">development</font> efforts and <font color="blue">provide access</font> to     important <font color="blue"><font color="blue">intellectual</font> property</font> and know-how</td>
    </tr>
    <tr>
      <td>Their <font color="blue">activities</font> include, for     example,  support  in processing the <font color="blue">regulatory</font> filings of our product     <font color="blue">candidates</font> and funding <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our outside scientific <font color="blue">consultants</font>     and  <font color="blue">contractors</font> perform research, develop <font color="blue">technology</font> and processes to     advance and augment our <font color="blue">internal efforts</font> and <font color="blue">provide access</font> to important     <font color="blue"><font color="blue">intellectual</font> property</font> and know-how</td>
    </tr>
    <tr>
      <td>Their <font color="blue">activities</font> include, for example,     clinical  <font color="blue">evaluation</font>  of  our  <font color="blue">product <font color="blue">candidates</font></font>, product <font color="blue">development</font>     <font color="blue">activities</font> performed under our research <font color="blue"><font color="blue">collaboration</font>s</font>, research under     sponsored  research  <font color="blue"><font color="blue">agreement</font>s</font>  and  contract <font color="blue">manufacturing</font> services</td>
    </tr>
    <tr>
      <td><font color="blue">Collaborations </font><font color="blue">with established pharmaceutical</font> and bio<font color="blue">technology</font> companies     and academic, research and <font color="blue">public health <font color="blue">organizations</font> often provide</font> a     measure of <font color="blue">validation</font> of our product <font color="blue">development</font> efforts in the eyes of     securities analysts, investors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of     certain  of  our  <font color="blue"><font color="blue">potential product</font>s</font>, and therefore the success of our     business,  <font color="blue">depends on</font> the performance of our partners, <font color="blue">consultants</font> and     <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>If they do not <font color="blue">dedicate sufficient</font> time, <font color="blue">regulatory</font> or other     <font color="blue">technical resources</font> to the research and <font color="blue"><font color="blue">development</font> programs</font> for our product     <font color="blue">candidates</font> or if they do not perform their <font color="blue">obligation</font>s as expected, we may     experience delays in, and may be unable to continue, the preclinical or     clinical <font color="blue">development</font> of those <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Each of our <font color="blue"><font color="blue">collaboration</font>s</font>     and scientific consulting <font color="blue">relationship</font>s concludes at the end of the term     specified in the applicable <font color="blue">agreement</font> unless we and our <font color="blue">partners agree</font> to     extend the <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>Any of our partners may decline to extend the     <font color="blue">collaboration</font>, or may be willing to extend the <font color="blue">collaboration</font> only with a     <font color="blue">significant</font>ly reduced scope, for a number of scientific or business reasons</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for scientific <font color="blue">consultants</font> and partners in <font color="blue">gene therapy</font> is     intense</td>
    </tr>
    <tr>
      <td>We  may  be  unable  to  <font color="blue">successfully</font>  maintain our existing     <font color="blue">relationship</font>s  or establish <font color="blue">additional</font> <font color="blue">relationship</font>s <font color="blue">necessary</font> for the     <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If we     are unable to do so, our research and <font color="blue"><font color="blue">development</font> programs</font> may be delayed or     we <font color="blue">may lose access</font> to important <font color="blue"><font color="blue">intellectual</font> property</font> or know-how</td>
    </tr>
    <tr>
      <td>The success of our <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">preclinical studies may</font> not be     <font color="blue">indicative</font> of results in a large number of subjects of <font color="blue">either safety</font> or     efficacy</td>
    </tr>
    <tr>
      <td>The successful results of our <font color="blue">technology</font> in <font color="blue">preclinical studies using</font>     <font color="blue">animal models may</font> not be predictive of the results that we will see in our     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, results in early-stage <font color="blue"><font color="blue">clinical trial</font>s</font> are     <font color="blue">based on</font> limited numbers of subjects and <font color="blue">generally test</font> for <font color="blue">drug safety</font>     <font color="blue">rather than efficacy</font></td>
    </tr>
    <tr>
      <td>Our reported progress and results from our early     phases of <font color="blue">clinical testing</font> of our <font color="blue">product <font color="blue">candidates</font></font> may not be <font color="blue">indicative</font>     of progress or results that will be achieved from larger populations, which     could be less favorable</td>
    </tr>
    <tr>
      <td>Moreover, we do not know if the favorable results     we  have achieved in <font color="blue"><font color="blue">clinical trial</font>s</font> will have a lasting or repeatable     effect</td>
    </tr>
    <tr>
      <td>If a larger group of subjects does not experience positive results     or if any favorable results do not <font color="blue">demonstrate</font> a <font color="blue">beneficial</font> effect, our     <font color="blue">product <font color="blue">candidates</font></font> that we advance to <font color="blue"><font color="blue">clinical trial</font>s</font>, may not receive     approval from the FDA for further <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>For     example, in March 2005, we <font color="blue">discontinued</font> the <font color="blue">development</font> of tgAAVCF following     the analysis of <font color="blue">Phase II </font><font color="blue">clinical trial</font> data in which tgAAVCF failed to     achieve the <font color="blue">efficacy endpoints</font> of the trial</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">adequately protect</font> our <font color="blue"><font color="blue">proprietary</font> rights</font> <font color="blue">domestically</font>     or overseas, which may limit our ability to <font color="blue">successfully</font> market any product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends <font color="blue">substantially</font> on</font> our ability to protect our     <font color="blue"><font color="blue">proprietary</font> rights</font> and operate <font color="blue">without infringing on</font> the <font color="blue"><font color="blue">proprietary</font> rights</font>     of others</td>
    </tr>
    <tr>
      <td>We own or license patents and patent <font color="blue">applications</font>, and will need     to  license  <font color="blue">additional</font>  patents,  for genes, processes, practices and     <font color="blue"><font color="blue">techniques</font> critical</font> to our present and potential <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we     fail to obtain and maintain patent or other <font color="blue"><font color="blue">intellectual</font> property</font> protection     for this                                         21       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font><font color="blue">technology</font>, our <font color="blue"><font color="blue">competitors</font> could market competing products using</font> those     genes, processes, practices and <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent process</font> takes several     years and involves considerable expense</td>
    </tr>
    <tr>
      <td>In addition, patent <font color="blue">applications</font>     and <font color="blue">patent positions</font> in the field of bio<font color="blue">technology</font> are <font color="blue">highly uncertain</font> and     involve  complex  legal,  scientific and factual questions</td>
    </tr>
    <tr>
      <td>Our patent     <font color="blue">applications</font> may not result in issued patents and the scope of any patent     may be <font color="blue">reduced both</font> before and after the patent is issued</td>
    </tr>
    <tr>
      <td>Even if we secure     a patent, the <font color="blue">patent may</font> not provide <font color="blue">significant</font> protection and may be     <font color="blue">circumvented</font> or invalidated</td>
    </tr>
    <tr>
      <td>We also rely on unpatented <font color="blue">proprietary</font> <font color="blue">technology</font> and <font color="blue">technology</font> that     we have <font color="blue">licensed on</font> a non<font color="blue">exclusive basis</font></td>
    </tr>
    <tr>
      <td>While we take <font color="blue">precautions</font> to     protect  our  <font color="blue">proprietary</font>  unpatented  <font color="blue">technology</font>, we may be unable to     <font color="blue">meaningfully</font>   protect   this  <font color="blue">technology</font>  from  <font color="blue">unauthorized</font>  use  or     <font color="blue">misappropriation by</font> a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> <font color="blue">could also</font></font> obtain rights     to our <font color="blue">nonexclusively</font> licensed <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In any event, other     companies may <font color="blue">independently</font> develop equivalent <font color="blue">proprietary</font> information and     <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop and market competing products using     our  unpatented  or  <font color="blue">nonexclusively</font> licensed <font color="blue">proprietary</font> <font color="blue">technology</font> or     <font color="blue">substantially</font> similar <font color="blue">technology</font>, our products, if <font color="blue">successfully</font> developed,     <font color="blue">could suffer</font> a reduction in sales or be <font color="blue">forced out</font> of the market</td>
    </tr>
    <tr>
      <td>If we do not develop adequate <font color="blue">development</font>, <font color="blue">manufacturing</font>, sales, marketing     and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font>, either alone or with our business partners,     we will be unable to generate sufficient <font color="blue">product revenue</font> to maintain our     business</td>
    </tr>
    <tr>
      <td>Our  potential  products require <font color="blue">significant</font> <font color="blue">development</font> of new     processes and design for the <font color="blue">advancement</font> of the <font color="blue">product candidate</font> through     <font color="blue">manufacture</font>, preclinical and <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>We may be unable to continue     <font color="blue">development</font> or <font color="blue">meet critical milestones with</font> our <font color="blue">partners due</font> to technical     or <font color="blue">scientific issues</font> related to <font color="blue">manufacturing</font> or <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We currently     do not have the <font color="blue">physical capacity</font> to <font color="blue">manufacture</font> large-scale quantities of     our  <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could limit</font> our ability to conduct large     clinical  trials  of  a <font color="blue">product candidate</font> and to <font color="blue">commercially launch</font> a     successful <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">manufacture</font> product at such scale,     we  will need to expand or improve our <font color="blue">current facilities</font> and staff or     <font color="blue">supplement them through</font> the use of <font color="blue">contract providers</font></td>
    </tr>
    <tr>
      <td>If we are unable to     obtain and maintain the <font color="blue">necessary</font> <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, either alone     or <font color="blue">through third parties</font>, we will be unable to <font color="blue">manufacture</font> our potential     products in <font color="blue">quantities sufficient</font> to sustain our business</td>
    </tr>
    <tr>
      <td>Moreover, we are     unlikely to <font color="blue">become profitable</font> if we, or our <font color="blue">contract providers</font>, are unable     to <font color="blue">manufacture</font> our <font color="blue"><font color="blue">potential product</font>s</font> in a cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>In  addition,  we  have  no  experience in sales, marketing and     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">successfully</font> <font color="blue">commercialize</font> any products that may result     from our <font color="blue"><font color="blue">development</font> programs</font>, we will need to develop these <font color="blue">capabilities</font>,     <font color="blue">either on</font> our own or <font color="blue">with others</font></td>
    </tr>
    <tr>
      <td>We intend to enter into <font color="blue"><font color="blue">collaboration</font>s</font>     with other entities to utilize their <font color="blue">mature marketing</font> and <font color="blue">distribution</font>     <font color="blue">capabilities</font>, but we may be unable to <font color="blue">enter into marketing</font> and <font color="blue">distribution</font>     <font color="blue"><font color="blue">agreement</font>s</font>  on  favorable  terms,  if at all</td>
    </tr>
    <tr>
      <td>If our current or future     <font color="blue">collaborative</font>  partners  do  not <font color="blue">commit sufficient resources</font> to timely     marketing and <font color="blue">distributing</font> our <font color="blue">future products</font>, if any, and we are unable to     develop the <font color="blue">necessary</font> marketing and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font> on our own, we     will  be  unable to generate sufficient <font color="blue">product revenue</font> to sustain our     business</td>
    </tr>
    <tr>
      <td>Post-approval <font color="blue">manufacturing</font> or <font color="blue">product problems</font> or failure to satisfy     applicable <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> could prevent or limit our ability to     market our products</td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of any <font color="blue">products will</font> require <font color="blue">continued compliance</font>     with FDA and other federal, state and <font color="blue">local <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>For example, our     current <font color="blue">manufacturing</font> <font color="blue">facility</font>, which is designed for <font color="blue">manufacturing</font> our AAV     vectors  for clinical and <font color="blue">development</font> purposes, is subject to the Good     Manufacturing Practices <font color="blue"><font color="blue">requirement</font>s</font> and other <font color="blue">regulations</font> of the FDA, as     well  as  to  other  federal,  state and <font color="blue">local <font color="blue">regulations</font></font> such as the     Occupational Health and Safety Act, the Toxic Substances Control Act, the     Resource Conservation and Recovery Act and the Environmental Protection Act</td>
    </tr>
    <tr>
      <td>Any future <font color="blue">manufacturing</font> facilities that we <font color="blue">may construct</font> for large-scale     <font color="blue">commercial production will also</font> be subject to regulation</td>
    </tr>
    <tr>
      <td>We may be unable     to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for or maintain in operation this or any other     <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In addition, we may be unable to attain or maintain     <font color="blue"><font color="blue">compliance with</font> current</font> or future <font color="blue">regulations</font> relating to <font color="blue">manufacture</font>,     safety,  handling,  storage,  record keeping or marketing of potential     products</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> or     discover previously unknown <font color="blue">manufacturing</font>, <font color="blue">contamination</font>, product side     effects or                                         22       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>other problems after we receive <font color="blue"><font color="blue">regulatory</font> approval</font> for a <font color="blue">potential product</font>,     we  <font color="blue">may suffer restrictions on</font> our ability to market the product or be     required to withdraw the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry       Adverse events in the field of <font color="blue"><font color="blue">gene therapy</font> could damage public <font color="blue">perception</font></font>     of our <font color="blue"><font color="blue">potential product</font>s</font> and <font color="blue">negatively affect <font color="blue">government</font>al approval</font> and     regulation</td>
    </tr>
    <tr>
      <td>Public  <font color="blue">perception</font> of our <font color="blue">product <font color="blue">candidates</font></font> could be <font color="blue">harmed by</font>     negative  events  in the field of <font color="blue">gene transfer</font></td>
    </tr>
    <tr>
      <td>For example, in 2003,     <font color="blue">fourteen subjects</font> in a French academic <font color="blue">clinical trial</font> being treated for     x-linked severe combined immunodeficiency in a <font color="blue"><font color="blue">gene therapy</font> trial using</font> a     <font color="blue">retroviral vector showed correction</font> of the disease, although three of the     <font color="blue">subjects subsequently</font> developed leukemia</td>
    </tr>
    <tr>
      <td>Serious <font color="blue">adverse events</font>, including     <font color="blue">patient deaths</font> have occurred in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Adverse events in our     <font color="blue"><font color="blue">clinical trial</font>s</font> and the resulting publicity, as well as any other adverse     events in the field of <font color="blue">gene therapy</font> that may occur in the future, could     result in a decrease in demand for any products that we may develop</td>
    </tr>
    <tr>
      <td>The     <font color="blue">commercial success</font> of our <font color="blue">product <font color="blue">candidates</font></font> will depend in part on public     <font color="blue">acceptance</font> of the use of <font color="blue">gene therapy</font> for preventing or <font color="blue">treating human</font>     diseases</td>
    </tr>
    <tr>
      <td>If public <font color="blue">perception</font> is <font color="blue">influenced by</font> claims that <font color="blue">gene therapy</font> is     unsafe, our <font color="blue">product <font color="blue">candidates</font></font> may not be <font color="blue">accepted by</font> the <font color="blue">general public</font> or     the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>The public and the <font color="blue">medical community</font> may conclude     that our <font color="blue">technology</font> is unsafe</td>
    </tr>
    <tr>
      <td>Future <font color="blue">adverse events</font> in <font color="blue">gene therapy</font> or the bio<font color="blue">technology</font> industry     <font color="blue">could also</font> result in greater <font color="blue">government</font>al regulation, unfavorable public     <font color="blue">perception</font>, stricter labeling <font color="blue"><font color="blue">requirement</font>s</font> and potential <font color="blue">regulatory</font> delays     in the testing or approval of our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>Any increased scrutiny     <font color="blue">could delay</font> or increase the costs of our product <font color="blue">development</font> efforts or     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our use of <font color="blue"><font color="blue">hazardous</font> materials exposes us</font> to <font color="blue">liability</font> risks and <font color="blue">regulatory</font>     <font color="blue">limitations on</font> their use, either of <font color="blue">which could reduce</font> our ability to     generate <font color="blue">product revenue</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous</font>  materials,  including  <font color="blue">chemicals</font>,  <font color="blue">biological materials</font> and     <font color="blue">radioactive compounds</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">safety procedures</font> for handling, storing and     disposing of these materials must <font color="blue">comply with</font> federal, state and <font color="blue">local laws</font>     and  <font color="blue">regulations</font>, including, <font color="blue">among others</font>, those relating to solid and     <font color="blue">hazardous</font> waste management, biohazard material handling, radiation and air     <font color="blue">pollution control</font></td>
    </tr>
    <tr>
      <td>We may be required to incur <font color="blue">significant</font> costs in the     future  to  comply  with  <font color="blue">environment</font>al  or  other <font color="blue">applicable laws</font> and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In  addition, we <font color="blue">cannot eliminate</font> the risk of <font color="blue"><font color="blue">accident</font>al</font>     <font color="blue">contamination</font> or injury from <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>If a <font color="blue">hazardous</font> material     <font color="blue">accident</font> were to occur, we could be held liable for any resulting damages,     and this <font color="blue">liability</font> could exceed our insurance and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td><font color="blue">Accidents </font>unrelated to our <font color="blue">operations</font> could cause federal, state or local     <font color="blue">regulatory</font> agencies to restrict our access to <font color="blue">hazardous</font> materials needed in     our research and <font color="blue">development</font> efforts, which could result in delays in our     research and <font color="blue"><font color="blue">development</font> programs</font></td>
    </tr>
    <tr>
      <td>Paying damages or experiencing delays     caused <font color="blue">by restricted access could reduce</font> our ability to <font color="blue">generate revenue</font> and     make it more <font color="blue">difficult</font> to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The intense <font color="blue">competition</font> and <font color="blue">rapid technological</font> change in our <font color="blue">market may</font>     result in failure of our <font color="blue"><font color="blue">potential product</font>s</font> to achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face increasingly intense <font color="blue">competition</font> from</font> a number of commercial     entities and <font color="blue">institution</font>s that are developing <font color="blue">gene therapy</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font>  include  early-stage  and  more <font color="blue">established gene delivery</font>     companies,  other  bio<font color="blue">technology</font>  companies, pharmaceutical companies,     <font color="blue">universities</font>, research <font color="blue">institution</font>s and <font color="blue"><font color="blue">government</font> agencies</font> developing gene     <font color="blue">therapy products</font> or other bio<font color="blue">technology</font>-based therapies designed to treat     the <font color="blue">diseases on which</font> we focus</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face <font color="blue">competition</font> from companies</font>     using  more <font color="blue">traditional approaches</font> to <font color="blue">treating human</font> diseases, such as     surgery,  medical  devices and <font color="blue">pharmaceutical products</font></td>
    </tr>
    <tr>
      <td>As our product     <font color="blue">candidates</font>  become  commercial  gene  <font color="blue">therapy products</font> that may affect     <font color="blue">commercial markets</font> of the <font color="blue">analogous protein</font> or <font color="blue">traditional pharmaceutical</font>     therapy, disputes including lawsuits, demands, threats or patent <font color="blue">challenges</font>     may arise in an effort to slow our <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">compete with</font>     other companies to acquire products or <font color="blue">technology</font> from research <font color="blue">institution</font>s     or <font color="blue">universities</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font>                                         23       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>more resources, including research and <font color="blue">development</font> personnel, capital and     <font color="blue">infrastructure</font>,  than we do</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> also have greater     experience and <font color="blue">capabilities</font> than we do in:         •  research and <font color="blue">development</font>;         •  <font color="blue"><font color="blue">clinical trial</font>s</font>;         •  obtaining FDA and other <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>;         •  <font color="blue">manufacturing</font>; and         •  marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>In  addition,  the  <font color="blue">competitive</font>  positions  of other companies,     <font color="blue">institution</font>s  and <font color="blue">organizations</font>, including smaller <font color="blue">competitors</font>, may be     strengthened  through  <font color="blue">collaborative</font>  <font color="blue">relationship</font>s</td>
    </tr>
    <tr>
      <td>Consequently, our     <font color="blue">competitors</font> may be able to develop, obtain <font color="blue">patent protection</font> for, obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for, or <font color="blue">commercialize</font> new products more <font color="blue">rapidly than</font> we     do, or <font color="blue">manufacture</font> and market <font color="blue">competitive</font> products more <font color="blue">successfully</font> than we     do</td>
    </tr>
    <tr>
      <td>This <font color="blue">could limit</font> the prices we <font color="blue">could charge</font> for the products that we are     able  to  market  or  result in our <font color="blue">products failing</font> to achieve market     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Gene therapy is a <font color="blue">rapidly evolving field</font> and is expected to continue     to undergo <font color="blue">significant</font> and <font color="blue">rapid technological</font> change and <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Rapid     </font>technological <font color="blue">development</font> by our <font color="blue">competitors</font>, including <font color="blue">development</font> of     <font color="blue">technologies</font>,  products  or  processes that are more <font color="blue">effective</font> or more     <font color="blue">economically feasible than</font> those we have developed, could result in our     actual and proposed <font color="blue">technologies</font>, products or <font color="blue">processes losing market</font> share     or <font color="blue">becoming obsolete</font></td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font><font color="blue">reform measures</font> and the un<font color="blue">willingness</font> of third-party payors to     <font color="blue">provide adequate <font color="blue">reimbursement</font></font> for the cost of our <font color="blue">products <font color="blue">could impair</font></font> our     ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue"><font color="blue">potential product</font>s</font> and become     profitable</td>
    </tr>
    <tr>
      <td>Sales of medical products and <font color="blue">treatments</font> depends <font color="blue">substantially</font>, both     <font color="blue">domestically</font>  and  abroad, on the <font color="blue">availability</font> of <font color="blue">reimbursement</font> to the     consumer  from  third-party  payors</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">potential product</font>s</font> may not be     considered  cost-<font color="blue">effective</font>  by third-party payors, who may not provide     <font color="blue">coverage at</font> the price set for our products, if at all</td>
    </tr>
    <tr>
      <td>If purchasers or     users of our products are unable to obtain adequate <font color="blue">reimbursement</font>, they may     forego or reduce their use of our products</td>
    </tr>
    <tr>
      <td>Even if coverage is provided,     the approved <font color="blue">reimbursement</font> amount may not be <font color="blue">high enough</font> to allow us to     establish or maintain <font color="blue">pricing sufficient</font> to realize a <font color="blue">sufficient return on</font>     our <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font><font color="blue">efforts by <font color="blue">government</font>al</font> and third-party payors, such as     Medicare, <font color="blue">private insurance</font> plans and managed care <font color="blue">organizations</font>, to cap or     <font color="blue">reduce healthcare costs will affect</font> our ability to <font color="blue">commercialize</font> our product     <font color="blue">candidates</font> and <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We believe that third-party payors will     attempt to <font color="blue">reduce healthcare costs by limiting both coverage</font> and level of     <font color="blue">reimbursement</font> for <font color="blue">new products approved by</font> the FDA There have been and will     continue  to  be  a number of federal and state proposals to implement     <font color="blue"><font color="blue">government</font> controls on pricing</font>, the adoption of <font color="blue">which could affect</font> our     ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Even if the     <font color="blue">government</font> does not adopt any <font color="blue">such proposals</font> or reforms, their <font color="blue">announcement</font>     <font color="blue">could impair</font> our ability to <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock       If we are unable to <font color="blue">comply with</font> the minimum <font color="blue"><font color="blue">requirement</font>s</font> for <font color="blue">quotation on</font>     the <font color="blue">NASDAQ Capital Market</font> and we may be delisted from the NASDAQ Capital     Market, the liquidity and <font color="blue">market price</font> of our <font color="blue">common stock</font> would decline</td>
    </tr>
    <tr>
      <td>Our stock is listed on the <font color="blue">NASDAQ Capital Market</font></td>
    </tr>
    <tr>
      <td>In order to continue     to  be  listed  on  the  NASDAQ  Capital Market, we <font color="blue">must meet specific</font>     <font color="blue">quantitative standards</font>, including maintaining a <font color="blue">minimum bid price</font> of dlra1dtta00     for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>On May 31, 2005, we received a notice from the NASDAQ     Stock Market <font color="blue">informing us</font> that for 30 <font color="blue">consecutive</font> business days the bid     price of our <font color="blue">common stock</font> had closed below the minimum dlra1dtta00 per share     <font color="blue">requirement</font> for <font color="blue">continued inclusion under</font> <font color="blue">Marketplace Rule </font>4310(c)(4)</td>
    </tr>
    <tr>
      <td><font color="blue">The                                         </font>24       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>letter stated that under <font color="blue">Marketplace Rule </font>4310(c)(8)(d), we were provided     with 180 calendar days, or until November 28, 2005, to <font color="blue">regain compliance</font>     with <font color="blue">Marketplace Rule </font>4310(c)(4)</td>
    </tr>
    <tr>
      <td>To <font color="blue">regain compliance</font>, the bid price of our     <font color="blue">common stock</font> must close at dlra1dtta00 per share or more for a minimum of 10     <font color="blue">consecutive</font> business days</td>
    </tr>
    <tr>
      <td><font color="blue">As of November </font>28, 2005, we had not regained     <font color="blue">compliance with</font> Market place Rule 4310(c)</td>
    </tr>
    <tr>
      <td>However, since we met all of the     NASDAQ Stock Market’s <font color="blue">criteria set forth</font> in <font color="blue">Marketplace Rule </font>4310(c), except     for the bid price <font color="blue">requirement</font>, the NASDAQ <font color="blue">provided us with</font> an <font color="blue">additional</font> 180     <font color="blue">calendar day compliance period</font>, or until May 26, 2006, to <font color="blue">demonstrate</font> full     compliance and maintain our <font color="blue">listing on</font> the <font color="blue">NASDAQ Capital Market</font></td>
    </tr>
    <tr>
      <td>To date,     we have not achieved the required <font color="blue">minimum bid price</font></td>
    </tr>
    <tr>
      <td>If we have not regained     <font color="blue">compliance at</font> that time, the <font color="blue">NASDAQ Staff </font><font color="blue">will provide written notification</font>     that our <font color="blue">securities will</font> be delisted</td>
    </tr>
    <tr>
      <td>Upon <font color="blue">delisting from</font> the <font color="blue">NASDAQ Capital Market</font>, trading, if any, in our     shares  <font color="blue">may continue</font> to be <font color="blue">conducted on</font> the <font color="blue">OTC Bulletin Board </font>or in a     non-NASDAQ over-the-counter market, such as the “<font color="blue">pink sheets</font></td>
    </tr>
    <tr>
      <td>” <font color="blue">Delisting </font>of     our shares would result in limited release of the <font color="blue">market price</font> of those     shares and limited <font color="blue">analyst coverage</font> and could restrict investors’ interest     in our securities</td>
    </tr>
    <tr>
      <td>Also, a delisting could have a material adverse effect on     the  trading market and prices for our shares and our ability to issue     <font color="blue">additional</font> securities or to secure <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td>In addition, if our     shares were not listed and the <font color="blue">trading price</font> of our shares was less than     dlra5 per share, our <font color="blue">shares could</font> be subject to Rule 15g-9 under the Securities     Exchange  Act of 1934 which, among other things, requires that broker/     dealers  satisfy special sales practice <font color="blue"><font color="blue">requirement</font>s</font>, including making     <font color="blue">individualized</font>  written  <font color="blue">suitability</font>  de<font color="blue">termination</font>s  and  receiving a     purchaser’s written consent prior to any <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>In such case, our     securities <font color="blue">could also</font> be deemed to be a “penny stock” under the Securities     Enforcement  and  Penny  Stock Reform Act of 1990, which would require     <font color="blue">additional</font> <font color="blue">disclosure</font> in <font color="blue">connection</font> with trades in those shares, including     the delivery of a <font color="blue">disclosure</font> schedule explaining the nature and risks of the     <font color="blue">penny <font color="blue">stock market</font></font></td>
    </tr>
    <tr>
      <td>Such <font color="blue"><font color="blue">requirement</font>s</font> could severely limit the liquidity of     our securities</td>
    </tr>
    <tr>
      <td>If we sell <font color="blue">additional</font> shares, our <font color="blue">stock price may decline as</font> a result of the     <font color="blue">dilution which will</font> occur to <font color="blue">existing stockholders</font></td>
    </tr>
    <tr>
      <td>Until we are profitable, we will need <font color="blue">significant</font> <font color="blue">additional</font> funds to     develop our business and sustain our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">additional</font> sales of     shares of our <font color="blue">common stock</font> are likely to have a dilutive effect on our then     <font color="blue">existing stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent </font>sales of these shares in the <font color="blue">open market</font>     <font color="blue">could also</font> have the effect of lowering our stock price, thereby increasing     the number of shares we may need to issue in the future to raise the same     <font color="blue">dollar amount</font> and <font color="blue">consequently further diluting</font> our <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>These future sales <font color="blue">could also</font> have an adverse effect on the <font color="blue">market price</font> of     our shares and could result in <font color="blue">additional</font> dilution to the holders of our     shares</td>
    </tr>
    <tr>
      <td><font color="blue">Concentration </font>of ownership of our <font color="blue">common stock</font> may give certain <font color="blue">shareholders</font>     <font color="blue">significant</font> influence over our business</td>
    </tr>
    <tr>
      <td>A small number of investors own a <font color="blue">significant</font> number of shares of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, Elan held approximately 11dtta6 million     and <font color="blue">Biogen Idec </font>held approximately 11dtta7 million shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Together these holdings represent approximately 27dtta2prca of our <font color="blue">common shares</font>     <font color="blue">outstanding as</font> of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of <font color="blue">stock ownership</font>     may allow these <font color="blue">shareholders</font> to                                         25       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>exercise <font color="blue">significant</font> control over our <font color="blue">strategic decisions</font> and block, delay     or <font color="blue">substantially</font> influence all matters requiring shareholder approval, such     as:         •  election of <font color="blue">directors</font>;         •  <font color="blue">amendment</font> of our <font color="blue">charter documents</font>; or         •  approval of <font color="blue">significant</font> corporate <font color="blue">transaction</font>s, such as a change of     control of <font color="blue">Targeted Genetics</font></td>
    </tr>
    <tr>
      <td>The interests of these <font color="blue">shareholders</font> may conflict with the interests of     other holders of our <font color="blue">common stock</font> with regard to <font color="blue">such matters</font></td>
    </tr>
    <tr>
      <td>Furthermore,     this  <font color="blue">concentration</font> of ownership of our common <font color="blue">stock could</font> allow these     <font color="blue">shareholders</font> to delay, deter or prevent a <font color="blue">third party</font> from acquiring control     of <font color="blue">Targeted Genetics</font> at a <font color="blue">premium over</font> the then-current <font color="blue">market price</font> of our     <font color="blue">common stock</font>, which could result in a decrease in our stock price</td>
    </tr>
    <tr>
      <td>Both <font color="blue">Biogen Idec </font>and Elan have sold shares of our <font color="blue">common stock</font> and may     continue to do so</td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with</font> the <font color="blue">termination</font> <font color="blue">agreement</font> that we     <font color="blue">entered into with</font> Elan with in March 2004, Elan is <font color="blue">only permitted</font> to sell     quantities of stock our equal to 175prca of the <font color="blue">volume limitation set forth</font> in     Rule 144(e)(1) promulgated under the <font color="blue">Securities Act </font>of 1933, as amended</td>
    </tr>
    <tr>
      <td>Market <font color="blue">fluctuations</font> or <font color="blue"><font color="blue">volatility</font> could</font> cause the <font color="blue">market price</font> of our common     stock to decline and limit our ability to <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> in general and the market for bio<font color="blue">technology</font>-related     companies  in  particular  have  experienced  <font color="blue">extreme price</font> and volume     <font color="blue">fluctuations</font>, often unrelated to the operating performance of the affected     companies</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of the securities of bio<font color="blue">technology</font> companies,     <font color="blue">particularly companies such as ours without earnings</font> and <font color="blue">product revenue</font>,     has <font color="blue">been highly volatile</font> and is likely to remain so in the future</td>
    </tr>
    <tr>
      <td>Any     report  of  clinical  trial results that are below the <font color="blue">expectations</font> of     <font color="blue">financial analysts</font> or <font color="blue">investors could</font> result in a decline in our stock     price</td>
    </tr>
    <tr>
      <td>We believe that in the past, similar levels of <font color="blue">volatility</font> have     <font color="blue">contributed</font> to the decline in the <font color="blue">market price</font> of our <font color="blue">common stock</font>, and may     do so again in the future</td>
    </tr>
    <tr>
      <td>Trading volumes of our <font color="blue">common stock</font> can increase     <font color="blue">dramatically</font>, resulting in a volatile <font color="blue">market price</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">trading price</font> of our common <font color="blue">stock could</font> decline <font color="blue">significant</font>ly as a result of     sales  of  a  substantial number of shares of our <font color="blue">common stock</font>, or the     <font color="blue">perception</font> that <font color="blue">significant</font> sales could occur</td>
    </tr>
    <tr>
      <td>In addition, the sale of     <font color="blue">significant</font> quantities of stock by Elan, <font color="blue">Biogen Idec </font>or other holders of     <font color="blue">significant</font> amounts of shares of our stock, could adversely impact the price     of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>